Jatenzo Cost in Mississippi (2026): Pricing, Insurance, and Savings Options

What Jatenzo Actually Costs at Mississippi Pharmacies

The average cash-pay price for Jatenzo at Mississippi retail pharmacies in 2026 sits at approximately $900 per month, matching the manufacturer list price set by Tolmar Pharmaceuticals. That figure applies to a 30-day supply of oral testosterone undecanoate capsules at standard dosing.

No generic version of Jatenzo exists as of May 2026. The drug received FDA approval in March 2019 as the first oral testosterone replacement therapy for adult men with hypogonadism who have conditions associated with structural or genetic etiologies. Patent protections keep pricing firmly in branded territory. The approval was based on a key trial by Swerdloff et al. (N=166) that demonstrated 87% of men achieved average testosterone concentrations within the normal range (300 to 1 to 100 ng/dL) after dose titration over 12 months [1]. Mississippi has no state-level drug price cap legislation that would reduce this figure below the manufacturer's set price. Pharmacy-level variation across the state is minimal because of limited competition in branded TRT dispensing. Rural pharmacies in the Delta region or on the Gulf Coast may need to special-order the medication, which does not change the price but can add 2 to 5 business days to fulfillment.

Patients paying cash should always ask the dispensing pharmacy to run any available discount cards before processing the transaction.

Mississippi Medicaid and Jatenzo: Current Coverage Status

Mississippi Medicaid does not cover Jatenzo. This exclusion applies to both fee-for-service Medicaid and managed care organizations (MCOs) operating under the Mississippi Division of Medicaid.

The state's Medicaid preferred drug list (PDL) includes injectable testosterone cypionate and topical testosterone gels as covered formulations for male hypogonadism. Oral testosterone undecanoate does not appear on the PDL, and prior authorization requests for Jatenzo through Mississippi Medicaid are routinely denied. The Endocrine Society's 2018 clinical practice guideline on testosterone therapy recommends treatment for men with symptomatic testosterone deficiency confirmed by two morning serum testosterone measurements below 300 ng/dL, but the guideline does not mandate any specific formulation over another.

Mississippi Medicaid beneficiaries with confirmed hypogonadism have access to testosterone cypionate injections (typically $30 to $80 per month) and topical testosterone preparations as covered alternatives. Men who specifically require an oral formulation due to injection anxiety, skin reactions to topical products, or secondary transfer concerns may have limited options under Medicaid in this state.

Dual-eligible patients (Medicare plus Medicaid) should check their Medicare Part D plan formulary separately. Some Part D plans cover Jatenzo at a Tier 3 or Tier 4 level, though copays can still exceed $200 per month.

Which Commercial Insurance Plans Cover Jatenzo in Mississippi

Coverage varies by plan and carrier. Several major insurers operating in Mississippi, including Blue Cross Blue Shield of Mississippi, UnitedHealthcare, Aetna, and Cigna, have included Jatenzo on their formularies with prior authorization requirements and step therapy protocols.

Prior authorization for Jatenzo typically requires documentation of a confirmed testosterone deficiency diagnosis (two morning total testosterone levels below 300 ng/dL), failure or intolerance of at least one first-line testosterone formulation (usually injectable or topical), and a clinical rationale for oral therapy. A 2020 analysis published in the Journal of Clinical Endocrinology & Metabolism found that oral testosterone undecanoate maintained eugonadal testosterone levels in 87% of participants at the 158 mg twice-daily dose after titration, supporting its clinical efficacy for coverage decisions [1].

Step therapy is common. Most Mississippi commercial plans require the patient to have tried and failed (or documented medical reasons not to use) testosterone cypionate injections and at least one topical testosterone product before approving Jatenzo. The appeals process adds 30 to 60 days if an initial prior authorization is denied.

Employer-sponsored plans governed by ERISA (most large-employer plans in the state) follow the plan's own formulary decisions rather than state insurance mandates. Self-insured employers in Mississippi's manufacturing, gaming, and energy sectors may have more restrictive formularies that exclude branded oral testosterone entirely.

Patients should request a formulary exception letter from their prescribing physician. Include the specific clinical reason oral therapy is medically necessary: injection phobia documented in the chart, contact dermatitis from topical formulations, or risk of testosterone transfer to household members (children or pregnant partners).

How the Tolmar Savings Card Works in Mississippi

Tolmar Pharmaceuticals offers a manufacturer savings card for Jatenzo that can reduce the patient's copay to as low as $0 for commercially insured patients, subject to annual maximum benefit limits.

Eligibility requirements are straightforward. The patient must have commercial (private) insurance that covers Jatenzo, even partially. Government-insured patients (Medicaid, Medicare, Tricare, VA) are not eligible for the savings card. The card typically covers the difference between the patient's copay and a specified floor (often $0 to $75), up to a maximum annual benefit that Tolmar sets and may adjust periodically.

Activation takes about 5 minutes. Patients can enroll online through the Tolmar patient support website or by calling the number on the Jatenzo prescribing information. The savings card generates a BIN, PCN, and member ID that the pharmacy processes as a secondary payer at the point of sale.

Mississippi pharmacies that participate in the major pharmacy benefit manager (PBM) networks, including CVS Caremark, Express Scripts, and OptumRx, process these cards routinely. Independent pharmacies may need the pharmacist to manually enter the secondary claim. Patients should confirm that the pharmacy applies the card before leaving the counter.

The savings card does not reduce the list price of the drug. It reduces what the patient pays after insurance processes its portion. For patients whose insurance denies coverage entirely, the savings card provides no benefit.

Compounded Oral Testosterone Undecanoate in Mississippi

Licensed 503A compounding pharmacies in Mississippi can legally prepare oral testosterone undecanoate capsules for individual patients with valid prescriptions. This option can dramatically reduce monthly costs compared to branded Jatenzo.

Under federal law (Drug Quality and Security Act, Section 503A), a compounding pharmacy operating with a valid state license may compound medications, including testosterone undecanoate, based on an individual patient prescription from a licensed prescriber. Mississippi's Board of Pharmacy regulates 503A compounding pharmacies under state pharmacy law and requires compliance with USP standards.

Several points matter for Mississippi patients considering this route. The compounded product is not FDA-approved and does not carry the same bioequivalence data as Jatenzo. The Swerdloff et al. trial data [1] and the FDA approval specifically apply to the branded Jatenzo formulation with its proprietary Self-Emulsifying Drug Delivery System (SEDDS) technology, which enhances lymphatic absorption and reduces first-pass hepatic metabolism. A compounded oral testosterone undecanoate capsule may use different excipients, potentially affecting absorption characteristics.

Dr. Bradley Anawalt of the University of Washington, a co-author on the Endocrine Society's testosterone therapy guideline, has stated: "The absorption profile of oral testosterone undecanoate depends heavily on the formulation. Patients switching between branded and compounded versions should have testosterone levels rechecked to confirm adequate absorption" [2].

Blood level monitoring is non-negotiable when using compounded formulations. Check a serum testosterone level 3 to 5 hours after the morning dose (at steady state, typically after 1 week of consistent dosing) to verify the compounded product is achieving therapeutic concentrations.

Patients should verify that their compounding pharmacy holds current Mississippi Board of Pharmacy licensure and complies with USP 795 standards for non-sterile compounding.

Telehealth Access to Jatenzo in Mississippi

Mississippi permits telehealth prescribing of Jatenzo. A provider licensed in Mississippi can evaluate, diagnose, and prescribe oral testosterone undecanoate via a synchronous audio-video telehealth visit.

The Mississippi Telehealth Act (Miss. Code Ann. § 83-9-351) established a framework for telehealth services that includes prescribing of controlled and non-controlled substances. Testosterone is a Schedule III controlled substance under federal law, and Mississippi does not impose additional restrictions beyond the federal requirements for prescribing it via telehealth.

Standard clinical requirements still apply. The prescribing provider must confirm the hypogonadism diagnosis with laboratory documentation per Endocrine Society guidelines (two morning total testosterone measurements below 300 ng/dL, drawn between 7 AM and 10 AM), evaluate symptoms, and rule out contraindications including untreated obstructive sleep apnea, polycythemia (hematocrit above 50%), and a history of hormone-sensitive cancers [2].

Telehealth platforms operating in Mississippi must use providers who hold active Mississippi medical licenses. The prescription is transmitted electronically to the patient's preferred Mississippi pharmacy. HealthRX's telehealth platform connects patients with Mississippi-licensed physicians who can evaluate candidates for Jatenzo therapy, order required bloodwork through local Quest or Labcorp draw sites, and manage ongoing monitoring.

Follow-up labs at 3, 6, and 12 months after initiation should include total testosterone (drawn 3 to 5 hours post-dose), hematocrit, PSA (for men over 40), and a hepatic function panel. The FDA label for Jatenzo specifically warns about dose-dependent increases in blood pressure. Blood pressure monitoring at each follow-up is required.

Reducing Your Jatenzo Costs: A Mississippi-Specific Breakdown

Five strategies exist for lowering out-of-pocket costs in Mississippi, ranked by typical savings.

1. Compounded oral testosterone undecanoate. Largest potential savings. Requires a prescription and a licensed 503A pharmacy. Verify absorption with follow-up labs.

2. Tolmar savings card. For commercially insured patients only. Can reduce copays to $0 to $75. Does not help cash-pay or government-insured patients.

3. Prior authorization appeal. If your commercial insurance denied Jatenzo, file a formal appeal with clinical documentation of failed alternatives. Success rates vary, but documented intolerance to injectables and topicals strengthens the case.

4. Manufacturer patient assistance program. Tolmar offers a patient assistance program for uninsured or underinsured patients meeting income eligibility criteria (typically at or below 400% of the federal poverty level). Contact Tolmar directly for current program details and application forms.

5. Alternative TRT formulations. If cost is the primary barrier and you do not have a medical necessity for oral dosing, injectable testosterone cypionate ($30 to $80 per month) or generic topical testosterone ($50 to $150 per month) offer substantially lower price points. Both are available at Mississippi pharmacies and covered by Mississippi Medicaid.

The right choice depends on your insurance status, medical history, and clinical need for oral versus other formulations. Your prescribing physician or a HealthRX clinician can help determine which approach fits your situation.

Jatenzo Blood Pressure Monitoring: Why Mississippi Patients Should Pay Attention

The Jatenzo FDA label carries a boxed warning about dose-dependent increases in systolic blood pressure. In the open-label extension study, mean increases of 3 to 5 mmHg in systolic blood pressure were observed across dose groups [1]. Mississippi has the highest rate of hypertension among U.S. states, with approximately 44.8% of adults diagnosed with high blood pressure according to CDC data.

This intersection matters clinically. A Mississippi man starting Jatenzo may already carry hypertension as a comorbidity. The American Heart Association classifies blood pressure of 130/80 mmHg or higher as hypertension under current guidelines. Adding 3 to 5 mmHg on top of an already elevated baseline can push patients into a higher risk category.

Dr. Shalender Bhasin of Brigham and Women's Hospital, a leading researcher in testosterone therapy, has noted: "Any testosterone formulation that raises blood pressure requires careful cardiovascular risk assessment, particularly in populations with high baseline prevalence of hypertension and metabolic syndrome" [3].

Prescribers in Mississippi should obtain baseline blood pressure readings before starting Jatenzo and recheck at 1, 3, 6, and 12 months. Patients with blood pressure above 140/90 mmHg at any follow-up visit require antihypertensive optimization before continuing therapy. Home blood pressure monitoring (morning and evening readings, 3 days per week) provides more reliable data than office-only measurements.